CD274 and non-small cell lung carcinoma: A post-hoc analysis of three phase III trials revealed that patients who had PD-L1 positive NSCLC had high disease control rates (complete, PR and SD) during ICI rechallenge therapy, ranging from 75.8% to 83.3% [25–27].